药品试验数据专有权与药品专利权冲突之研究——从药品可及性角度谈起  

Study on the Conflict between the Exclusive Right of Drug Test Data and Drug Patent Right: From the Perspective of Drug Accessibility

作　　者：陈庆[1,2] 

机构地区：[1]中南财经政法大学知识产权研究中心 [2]南京师范大学泰州学院法学院

出　　处：《知识产权》2012年第12期56-61,共6页Intellectual Property

基　　金：教育部人文社会科学重点研究基地重大项目(编号:11JJD820006)基金资助

摘　　要：《TRIPS协定》下药品试验数据专有权为新药的申请提供排他性专有权保护,一定程度上起到类似专利权独占市场保护权的作用,其与药品专利权存在天然的冲突。如何正确解读《TRIPS协定》下对药品试验数据专有权的保护及如何协调其与专利权的冲突,对药品可及性及实现《多哈宣言》所倡导的为实现公共健康目的的精神有着重要的现实意义。Under the TRIPS agreement, the exclusive right of drug test data provides exclusive protection for the new drug, and to a certain extent, plays a similar part to patent right in protecting the exclusive market. But there is a natural conflict between the exclusive right of drug test data and drug patent right. How to correctly understand the TRIPS agreement on the protection of exclusive right of drug test data and how to coordinate the conflict between it and patent right is of important practical significance for the drug accessibility and for realizing the destination of ensuring public health proposed by Doha Declaration.

关 键 词：试验数据专有权 专利权 公共健康 冲突 

分 类 号：D997.1[政治法律—国际法学] F416.72[政治法律—法学]